Hibernaid, Inc.

The only pharmacologically induced method to achieve Therapeutic Hypothermia.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Troy, NY, USA
  • Currency USD
  • Founded June 2012
  • Employees 5
  • Incorporation Type C-corp
  • Website hibernaid.com

Company Summary

BioPharma IND-ready to initiate Ph-1 study in patients at University of Pittsburgh. HBN-1 is only pharmacologic method to reduce & maintain core body temp which is Amer Heart Assoc recommended treatment for resuscitated post-cardiac arrest. Over $1M in Founder $ invested as well as $3M NIH award for preclin program. Multi-$B global mkt. Pt study yields efficacy to trigger exit in late 2019, or option to continue to add further value.

Team

  • Stephen Petti

  • Laurence Katz, MD
    Chief Med Officer, co-founder

    Professor Emergency Med at Univ of NC, discovered HBN-1, acknowledged opinion leader in Therapeutic Hypothermia.

  • Melisa Barron
    Director of Chemistry, Manufacturing and Control

    20+ years in the field, numerous successful drug development programs. 6 years with the company

  • Kate Martin
    Director, Medical/Scientific Writing, FDA document preparation

    30 yrs experience with Big Pharma, consulting and IND, NDA filings.

  • Samn Raffaniello
    Co-Founder, VP, Finance Admin and Systems Support

    15 yrs Big Pharma responsible for $30M+ Clinical budgets for a 200 person research department. Three prior successful start-ups

  • Dr. Ronald Tribble
    Senior Business Advisor to CEO

    20 yrs in private dental practice, board participation and senior positions in various successful business ventures. Hibernaid investor.

Advisors

Previous Investors

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free